Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis
In this medfyle
Meta-analysis confirms IE impairment in T2D and obesity, and highlight new factors.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This summary is based upon an article appearing in the Journal of Clinical Endocrinology & Metabolism published by Oxford University Press and was created by GlobalPort. Oxford University Press takes no responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Prof. Filip K. Knop, MD, PhD, Denmark.
Original article:
Grespan E, Guolo A, Muscelli E, Ferrannini E, Mari A. Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2022 Jun 16;107(7):2092-2100. doi: 10.1210/clinem/dgac213. PMID: 35397169.
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries, and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of Endocrine Society/Oxford University Press.
This activity is supported by an educational grant from Lilly.
